Allogeneic cell therapy bioprocess economics and optimization: Single‐use cell expansion technologies

Abstract

For allogeneic cell therapies to reach their therapeutic potential, challenges related to achieving scalable and robust manufacturing processes will need to be addressed. A particular challenge is producing lot-sizes capable of meeting commercial demands of up to 109 cells/dose for large patient numbers due to the current limitations of expansion technologies. This article describes the application of a decisional tool to identify the most cost-effective expansion technologies for different scales of production as well as current gaps in the technology capabilities for allogeneic cell therapy manufacture. The tool integrates bioprocess economics with optimization to assess the economic competitiveness of planar and microcarrier-based cell expansion technologies. Visualization methods were used to identify the production scales where planar technologies will cease to be cost-effective and where microcarrier-based bioreactors become the only option. The tool outputs also predict that for the industry to be sustainable for high demand scenarios, significant increases will likely be needed in the performance capabilities of microcarrier-based systems. These data are presented using a technology S-curve as well as windows of operation to identify the combination of cell productivities and scale of single-use bioreactors required to meet future lot sizes. The modeling insights can be used to identify where future R&D investment should be focused to improve the performance of the most promising technologies so that they become a robust and scalable option that enables the cell therapy industry reach commercially relevant lot sizes. The tool outputs can facilitate decision-making very early on in development and be used to predict, and better manage, the risk of process changes needed as products proceed through the development pathway. Biotechnol. Bioeng. 2014;111: 69–83. © 2013 Wiley Periodicals, Inc.

From production to patient: challenges and approaches for delivering cell therapies

“…not a therapy for a life-threatening condition, but a remedial therapy for a moderately disabling condition with a global market). The simple calculation of the cells required may show that the growth surface required for the cells per annum mandates a very large facility if traditional disposable technologies, such as cell factories, roller bottles or T-flasks, are to be used (Simaria et al, 2014;Want et al, 2012). The choice of such methods is attractive in the sense that the growth environment is comparable to that which was applied during early development and proof-of-concept.…”

Robust Expansion of Human Pluripotent Stem Cells: Integration of Bioprocess Design With Transcriptomic and Metabolomic Characterization

“…Because massive numbers of hPSCs may be needed to address biomedical demands, namely, for cell therapy (e.g., 10 9 to 10 10 cells are required for heart or hepatic failure therapies) or drug-discovery pipelines (requiring ∼10 10 cells to screen a 1 million-compound library at once), the use of microcarrier-based bioreactors offers a more cost-effective system for high-production scales than planar technologies, as reported recently [9]. Our group and others have demonstrated successful expansion of hPSCs in stirred-tank bioreactors using different types of microcarriers [7,10,11].…”

Industry 4.0: a vision for personalized medicine supply chains?

“…[4][5][6][7]. This makes the benefits of Industry 4.0 with its vision of a self-organising factory less obvious for the biopharmaceutical industry.…”